Surrozen, Inc./DE

Churchill Capital Corp VII, trading under the ticker CHFW, was a blank-check company sponsored by Churchill Capital Group and formed to pursue an acquisition in the healthcare sector. The vehicle completed its initial public offering in early 2021 and subsequently identified Surrozen, Inc., a Delaware-incorporated biotechnology company focused on Wnt signaling pathway biology for tissue repair and organ regeneration, as its business combination target. The 10-Q filed on August 9, 2021, under accession number 0001193125-21-239469, reflects the combined entity's reporting obligations as the de-SPAC transaction with Surrozen moved toward or reached closing during that period. Sign up for a SpacDesk account to access the full filing history, deal timeline, and sponsor data for CHFW and hundreds of other SPAC transactions.